Login / Signup

Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?

Jie YangJia-Yan HuangXing ChenWen-Wu LingYan LuoYu-Jun ShiJi-Bin LiuQiang LuAndrej Lyshchik
Published in: European radiology (2021)
• By using the American College of Radiology contrast-enhanced ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS), majority (30/37, 81.1%) of cHCC-CCA tumors were classified as LR-M or LR-TIV and only 18.9% (7/30) of cHCC-CCA were categorized as LR-5. • Patients with CEUS LR-5 cHCC-CCA had statistically significant longer disease-free time than those with LR-M and TIV cHCC-CCA (median DFS: 18.0 vs 6.4 months, p = 0.016). • Multiple lesions (hazard ratio, 3.1; p = 0.007), tumor size (≥ 5 cm, hazard ratio, 4.1; p = 0.003), and CEUS LI-RADS category (LR-M and LR-TIV, hazard ratio, 4.7; p = 0.011) showed independent association with shorter DFS.
Keyphrases
  • contrast enhanced ultrasound
  • high resolution
  • big data
  • emergency department
  • adverse drug
  • case report
  • ion batteries
  • photodynamic therapy
  • mass spectrometry
  • free survival